Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

SMS-Oncology (Specialized Medical Services-Oncology B.V.). (4/21/16). "Press Release: €8.3 Million EU Grant Awarded to International »PRECIOUS« Consortium to Integrate Nanomedicines and Immunotherapy to Attack Cancer".

Region Region EU (European Union)
Organisations Organisation SMS-Oncology B.V. (Specialized Medical Services-Oncology B.V.)
  Group SMS-Oncology (Group)
  Organisation 2 PRECIOUS project (2) (scaling-up immunomodulating nanomedicines for multimodal precision cancer immunotherapy) (EU, FP8, 201605–202104)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 nanomedicine
Index term Index term PRECIOUS project (2)–EU (govt): grant, 201605–202104 Horizon 2020 grant €8.3m to develop cancer immuntherapeutic nanomedicine led by Radboud Univ
Persons Person Hoffmans, Raymond (SMS-Oncology 201504 Chief Business Development Manager)
  Person 2 Bosch, Lindy (SMS-Oncology 201602 Business Developer)
     


An international multi-disciplinary consortium of 11 partners, in which 5 leading academic institutes, 4 cutting-edge biotech companies and 2 excellent service providers will join forces to advance the treatment of cancer using an innovative immunotherapeutic nanomedicine, has received an €8.3 million Horizon 2020 grant (grant agreement No 686089). The PRECIOUS consortium will be coordinated by the awarded Prof. Dr. Carl Figdor, senior professor in Experimental Immunology and head of the Tumor Immunology Department of the Radboud University Medical Center, the Netherlands.

Novel treatment strategies for cancer are highly needed

Despite the access to different classical treatment strategies such as chemotherapy, radiotherapy and surgery, cancer is still a leading cause of death worldwide accounting for over 8 million deaths per year. Often, tumour cells that have become resistant to chemo- and radiotherapy ultimately lead to the death of a patient. Therefore, radically innovative approaches are highly needed to increase survival rates. In the past 5 years, immunotherapy has completely overhauled the cancer field with several new types of therapies entering the market at a rapid pace. The great benefit of immunotherapy is that it attacks tumour cells via a completely different mechanism than chemo- and radiotherapy, harnessing the power of the body’s own immune system to fight cancer. However, current immunotherapies are challenged by low efficacy, partially due to the immunosuppressive tumour microenvironment.

PRECIOUS will revolutionise cancer treatment

The PRECIOUS (scaling-up immunomodulating nanomedicines for multimodal precision cancer immunotherapy) project will establish a platform for the development of new medicines that contain immunomodulating components acting at multiple levels. ‘These novel medicines will act as a ‘two-sided knife’ by boosting the immune system, and at the same time attacking the immunosuppressive microenvironment that characterises the tumour site‘ Prof. Dr. C. Figdor says. Nanoparticles offer the optimal platform for a combinational immunotherapy, as they are able to encapsulate immunomodulators in biodegradable particles. Currently, immunomodulating nanomedicines are not used to their full potential due to is challenging manufacturing requirements. PRECIOUS will develop a manufacturing process at industrial scale for immunomodulating nanomedicines and test the potential of these nanoparticle based immunotherapies in the clinic. To ensure that these novel treatment strategies will reach patients, the development of a marketing and commercialisation strategy for these novel medicines is an important part of the project. Together, PRECIOUS will realise a major improvement in cancer therapy to provide cancer patients with enhanced quality of life.


About the consortium

The consortium consists of academic experts in the field from 5 leading institutes (RadboudUMC, University of Konstanz, Institute of Macromolecular Chemistry ASCR, University of Oxford and Fondazione IRCCS Istituto Nazionale dei Tumori) with outstanding track records in the fields of immunotherapy, tumour immunology, preclinical drug development and clinical trials. In addition, it includes cutting-edge biotech companies that will enable project results to be translated to the clinic. Evonik Nutrition & Care GmbH is the lead manufacturer of PLGA-based particles and will bring in invaluable expertise on manufacturing of nanomedicines. iTeos Therapeutics will develop and provide novel immunomodulators that target the tumour micro-environment. iOx Therapeutics and Oncoarendi Therapeutics will contribute their promising, novel immunomodulators (iNKT and ARG inhibitors respectively) to be part of the immunomodulating nanomedicine platform. SMS-oncology will support the clinical development path with their broad knowledge on clinical trial design and implementation. ttopstart, involved in developing the business cases of many leading cancer therapies and diagnostic tests, will be responsible for the business aspects of PRECIOUS by ensuring a strong exploitation strategy and tight project management. The combined expertise will allow the PRECIOUS consortium to truly perform translational research towards benefit of the most important stakeholder, cancer patients in need of novel treatment strategies. The project will kick off in May 2016 and has a duration of 60 months.


Contact

To learn more about the project, visit the EC website.


SMS-oncology is a full-service oncology Contract Research Organization (CRO) where clinical operations and consultancy services intertwine in what we refer to as our 4D concept. We add an extra dimension to clinical cancer research by providing direction to our sponsors. We are oncology drug development experts. Turning complex data into meaningful insights during clinical studies helps our sponsors to mitigate risks, identify opportunities and collect the right data to build their regulatory dossier.

For further information, please contact Raymond Hoffmans PhD (CBDO, r.hoffmans@sms-oncology.com, +31 (0)6 249 72 552) or Lindy Bosch MSc (Business Developer, l.bosch@sms-oncology.com, +31 (0)6 211 97 552).

An extra dimension in clinical cancer research
SMS-oncology | Science Park 408 | 1098 XH Amsterdam | The Netherlands
www.sms-oncology.com | +31 (0)20 4350 580


   
Record changed: 2019-07-08

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for SMS-Oncology (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top